Basilea Pharmaceutica AG provided product revenue guidance for the second half of 2023. The company expected a significant increase in product revenue with the second half of 2023 expected to account for around 65% of total full-year product revenue. Revenue from milestone payments is largely derisked for 2023 as the majority of milestone events expected for the year have already occurred in the first half of 2023.